Tirzepatide: A New Treatment in Diabetes and Obesity.
Tirzepatide is a once‑weekly subcutaneous injection developed by Eli Lilly, known for combining GLP‑1 and GIP receptor agonist activity. It’s prescribed to adults with type 2 diabetes to improve blood sugar control by enhancing insulin release, suppressing glucagon, and slowing gastric emptying euromedclinicdubai.com+15drugs.com+15en.wikipedia.org+15.
Tirzepatide delivers dual benefits: proven glucose control and substantial weight reduction—around 16–23 kg over 72 weeks, according to clinical trials en.wikipedia.org+1medindia.net+1euromedclinicdubai.com+15drugs.com+15drugs.com+15.
As always, it’s intended as part of a broader treatment plan including diet, exercise, and regular medical monitoring to ensure safety and effectiveness.
Every patient deserves access to advanced, affordable care. We are marking a major step in the treatment of diabetes and weight challenges. As we prepare to launch this powerful new solution, we’re committed to supporting healthier futures across our communities. For more information: communications@dawalifesciences.com
